"Comprehensive Blood and Cancer Center (CBCC) is a medical center that offers many services, including medical oncology & hematology, radiation oncology, and gynecologic oncology. Visit Comprehensive Blood and Cancer Center (CBCC) located at 6501 Truxtun Ave, Bakersfield, CA. This Bakersfield medical center is one of the best in California. As part of the Dignity Health network, Comprehensive Blood and Cancer Center (CBCC) is dedicated to delivering high quality, compassionate care and access to Bakersfield and nearby communities."

During the past decade, Comprehensive Blood And Cancer Center conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 54 clinical trials were completed, i.e. on average, 128.6% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 28 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Comprehensive Blood And Cancer Center" #1 sponsor was "Pfizer" with 11 trials, followed by "Eli Lilly and Company" with 8 trials sponsored, "Bristol-Myers Squibb" with 7 trials sponsored, "Novartis Pharmaceuticals" with 7 trials sponsored and "Oncotherapeutics" with 7 trials sponsored. Other sponsors include 59 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Comprehensive Blood And Cancer Center" #1 collaborator was "Genentech, Inc." with 4 trials as a collaborator, "Medivation, Inc." with 4 trials as a collaborator, "Hoffmann-La Roche" with 3 trials as a collaborator, "Sanofi" with 3 trials as a collaborator and "Bayer" with 2 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Comprehensive Blood And Cancer Center" are "Breast Cancer" (13 trials), "Multiple Myeloma" (9 trials), "Colorectal Cancer" (8 trials), "Non-small Cell Lung Cancer" (5 trials) and "Carcinoma, Non-Small-Cell Lung" (4 trials). Many other conditions were trialed in "Comprehensive Blood And Cancer Center" in a lesser frequency.

Most popular intervention types in "Comprehensive Blood And Cancer Center" are "Drug" (99 trials), "Biological" (8 trials), "Other" (8 trials), "Dietary Supplement" (2 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Docetaxel" (9 trials), "Bevacizumab" (7 trials), "Gemcitabine" (7 trials) and "Paclitaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "Comprehensive Blood And Cancer Center" are 83 trials for "All" genders, 18 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Comprehensive Blood And Cancer Center". undefined are not yet recruiting, 4 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 66 completed trials in Comprehensive Blood And Cancer Center, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Comprehensive Blood And Cancer Center, 15 "Phase 1" clinical trials were conducted, 49 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".